Source: Annual Congress 2005 - Biological and treatment aspects of tuberculosis
Disease area: Respiratory infections

Abstract

Neurotoxicity of Isiniazid is well-known. The authors describe the case of one patient who developped a vestibular syndrome after Isoniazid .
Ms FZ ,fifty two years old was admitted to pulmonary diseases department for pulmonary tuberculosis. Before instauring treatment she was given the dose of 5mg perKg of Isoniazid to perform an acetylation test.She developped by three hours later dizziness.Vestibular testing showed a loss of the right ear function. There wasn‘t any hearing loss in the audiogram. The cerebral magnetic resonance imaging didnt demonstrate any neurological lesion.The patient was a slow acetylor to Isoniazid.
Isoniazid vestibular toxicity hasn‘t been yet described in patients without other predisposing factors. Ototoxicite due to Isoniazid has been reported in patients undergoing hemodialysis for terminal renal failure. And vestibular toxicity has also been reported in patients receving Isoniazid in association to carbamazepine.

Rating:

Share or cite this content

Citations should be made in the following way:
S. Azzabi, H. Aouina, L. Gharbi, R. B. Mefteh, M. Azzouz, M. A. Baccar, H. Bouacha (Tunis, Tunisia). Vestibular toxicity, an unusual side effect of isoniazid. Eur Respir J 2005; 26: Suppl. 49, 2910

Member's Comments

No comment yet.

Related content which might interest you: The impact of ethambutol optic toxicity on treatment of MDR TB Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010 Efficacy of intravenous isoniazid, rifampin and ethambutol administration in patients with failed treatment of tuberculosis and malabsorption syndrome Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016 Rapid oral desensitisation to ethambutol, rifampicin and isoniazid Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009 The influence phenotype of hydroxylation on anti-tuberculosis drug-induced hepatotoxicity Source: Eur Respir J 2006; 28: Suppl. 50, 505s Year: 2006 Ethambutol optic toxicity: the importance of color perception testing Source: Eur Respir J 2006; 28: Suppl. 50, 505s Year: 2006 A case with rifampicin induced severe trombocytopenia during tuberculosis treatment Source: Annual Congress 2007 - Difficult tuberculosis cases I Year: 2007 Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016 In vitro susceptibility to rifampin and ethambutol and treatment outcome in MAC lung disease Source: International Congress 2018 – The global impact of bronchiectasis and nontuberculous mycobacteria (NTM) Year: 2018 Monitoring of amikacin-induced ototoxicity during the treatment of multidrug resistant tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012 Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB) Source: Annual Congress 2007 - Epidemiology of tuberculosis II Year: 2007 Pulmonary toxicity with mefloquine Source: Eur Respir J 2001; 18: 890-892 Year: 2001 Evaluation of therapeutic response in isoniazid resistant TB Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006 Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002 Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019 The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes Source: Eur Respir J 2004; 24: Suppl. 48, 654s Year: 2004 Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020